Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can boosted atazanavir induce hyperlipotrophy?

P Dellamonica1

  • 1Infectious Diseases Department, Nice University Hospital, Nice Cedex 3, France. infectiologie@chu-nice.fr

The Journal of Infection
|October 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diarrhea and HIV infection].

Medecine et maladies infectieuses·2024
Same author

[Rational use of antibiotics treatment in acute bronchitis].

Medecine et maladies infectieuses·2024
Same author

E-health. Patterns of use and perceived benefits and barriers among people living with HIV (PLHIV) and their physicians - Part 3: Telemedicine and collection of computerized personal information.

Medecine et maladies infectieuses·2020
Same author

E-health. Patterns of use and perceived benefits and barriers among people living with HIV and their physicians. Part 2: Health apps and smart devices.

Medecine et maladies infectieuses·2020
Same author

E-health. Patterns of use and perceived benefits and barriers among people living with HIV and their physicians. Part 1: Information retrieval on the Internet and social networks.

Medecine et maladies infectieuses·2020
Same author

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.

Journal of neurovirology·2016
Same journal

Age-associated impairment of humoral and cellular immune responses to SARS-CoV-2 in a large community cohort with hybrid immunity.

The Journal of infection·2026
Same journal

Genomic characterization of a large-scale chikungunya outbreak in China.

The Journal of infection·2026
Same journal

Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5/BF.7 breakthrough infection.

The Journal of infection·2026
Same journal

Multi-strain Clostridioides difficile infection: Increased detection and clinical implications.

The Journal of infection·2026
Same journal

A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment.

The Journal of infection·2026
Same journal

Defining the threshold duration of candidemia associated with poor outcomes: Redefining persistent candidemia.

The Journal of infection·2026
See all related articles

Individual differences in glucuronidation affect atazanavir levels, causing lipodystrophy and complicating dosage adjustments. This case highlights challenges in treating HIV/HCV co-infected patients with atazanavir.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Hepatology

Background:

  • Atazanavir is an effective protease inhibitor for HIV treatment.
  • Glucuronidation is a key metabolic pathway affecting drug clearance.
  • HIV/HCV co-infection presents complex treatment challenges.

Observation:

  • A patient with HIV and Hepatitis C co-infection was treated with atazanavir.
  • The patient experienced variations in serum atazanavir concentrations.

Findings:

  • Individual variations in glucuronidation led to altered atazanavir metabolism.
  • These metabolic differences resulted in lipodystrophy, a potential side effect.
  • Dosage adjustment of atazanavir proved difficult due to these variations.

Related Experiment Videos

Implications:

  • Highlights the importance of considering individual metabolic differences in drug therapy.
  • Suggests potential need for personalized dosing strategies for atazanavir.
  • Underscores the complexities of managing co-infections like HIV/HCV.